Rezafungin
 | |
| Names | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| Clinical data | |
| Drug class | Echinocandin[1] |
| Main uses | Invasive candidiasis[1] |
| Side effects | Low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, infusion reaction, sun sensitivity, liver problems[1] |
| Legal | |
| License data |
|
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.4 g/mol |
Rezafungin, sold under the brand name Rezzayo, is an antifungal medication used to treat invasive candidiasis, including candidemia.[1] Specifically it is used in adults with few or no alternative treatment options.[1][2] It is given by slow injection into a vein.[1]
Common side effects include low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, and constipation.[1] Other side effects may include infusion reactions, sun sensitivity, and liver problems.[1] Safety in pregnancy is unclear.[1] It is in the echinocandin class of medication.[1][3]
Rezafungin was approved for medical use in the United States in 2023.[1] It is expected to become available in the United States in the summer of 2023 and to be expensive.[4] It received an orphan medication designation in Europe in 2021.[5]
Medical uses
Dosage
It is given at an initial dose of 400 mg, which is followed by 200 mg once per week for three more weeks.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 "DailyMed - REZZAYO- rezafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 2 July 2023. Retrieved 21 June 2023.
- ↑ "Rezzayo approved by FDA amid rapid Candida auris spread". thepharmaletter.com. March 23, 2023. Archived from the original on July 1, 2023. Retrieved April 4, 2023.
- ↑ Zhao Y, Perlin DS (September 2020). "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data". Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
- ↑ "Rezafungin (Rezzayo)". IDStewardship. 23 March 2023. Archived from the original on 12 May 2023. Retrieved 21 June 2023.
- ↑ "EU/3/20/2385". European Medicines Agency. 18 May 2021. Archived from the original on 1 April 2023. Retrieved 22 June 2023.
External links
| Identifiers: |
|---|
 | This antiinfective drug article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Infobox-drug molecular-weight unexpected-character
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Echinocandins
- Ethers
- Phenyl compounds
- RTT
- All stub articles
- Antiinfective agent stubs